Polyneuropathy can cause pain, discomfort, and mobility difficulties. Learn more about the types, causes, and symptoms, as well as how to diagnose and treat the condition.

Treatment for chronic inflammatory demyelinating polyneuropathy can include intravenous immunoglobulin, corticosteroids, plasmapheresis, and Vyvgart Hytrulo.

Polyneuropathy Treatment Market Benefiting from Innovations in Neuromodulation Techniques and High Focus on Pain ManagementRockville, MD , Jan. 07, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a ...

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR), ...

Peripheral neuropathy (PN), ... As it prepares for WST-057’s final phase, WinSanTor is fast approaching its legacy as the first regenerative treatment for peripheral neuropathy.

--Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient has been dosed in ...

Netherlands-based argenx has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended its efgartigimod alfa treatment, brand name ...

Since hATTR with polyneuropathy impacts several organs and is a genetic disease, you’ll likely have to see several specialists to manage the disease. Your care team can include: Genetic counselor.

Treatment Side Effects: Peripheral neuropathy and other toxicities may be more common or more severe, leading to dose ...

- Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placebo ...

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...